All In Biotech

Drug Trial Radar · NCT01006265

Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis

Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy, Safety, and Tolerability of Three Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered for Twenty-four Weeks in Patients With Relapsing-remitting Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 464 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

464

Actual

Start

Oct 1, 2009

Primary completion

Jun 1, 2011

Study completion Jul 1, 2011

Sponsor

Lead sponsor
ActelionJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Nov 2, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the efficacy, safety, and tolerability of ACT-128800 in patients with relapsing-remitting multiple sclerosis.

Conditions

  • Multiple Sclerosis

Interventions

  • ACT-128800 Dose 1Drug

    ACT-128800 (Dose 1) administered orally once daily

  • PlaceboDrug

    Matching placebo administered orally once daily

  • ACT-128800 Dose 2Drug

    ACT-128800 (Dose 2) administered orally once daily

  • ACT-128800 Dose 3Drug

    ACT-128800 (Dose 3) administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative Number of New T1 Gadolinium-Enhancing (Gd+) Lesions on Magnetic Resonance Imaging (MRI) Scan From Week 12 to Week 24Time frame: From Week 12 to 24

Locations

115 sites in 23 countries. Site status is shown where the registry gives one.

  • Clinical Investigative Site 3132

    Scottsdale, Arizona

  • Clinical Investigative Site 3100

    Tucson, Arizona

  • Clinical Investigative Site 3115

    Sacramento, California

  • Clinical Investigative Site 3117

    Stanford, California

  • Clinical Invesigative Site 3116

    Sarasota, Florida

  • Clinical Investigative Site 3101

    Indianapolis, Indiana

  • Clinical Investigative Site 3105

    Kansas City, Kansas

  • Clinical Investigative Site 3107

    Lenexa, Kansas

  • Clinical Investigative Site 3118

    Baltimore, Maryland

  • Clinical Investigative Site 3133

    Worcester, Massachusetts

  • Clinical Investigator 3136

    St Louis, Missouri

  • Clinical Investigative Site # 3135

    Newark, New Jersey

  • Clinical Investigative Site 3129

    Latham, New York

  • Clinical Investigative Site # 3128

    New York, New York

  • Clinical Investigative Site 3127

    Schenectady, New York

  • Clinical Investigative Site 3120

    Stony Brook, New York

  • Clinical Investigative Site 3119

    Raleigh, North Carolina

  • Clinical Investigator 3126

    Akron, Ohio

  • Clinical Investigative Site 3113

    Cincinnati, Ohio

  • Clinical Investigative Site 3130

    Columbus, Ohio

  • Clinical Investigator 3104

    Portland, Oregon

  • Clinical Investigative Site 3125

    Philadelphia, Pennsylvania

  • Clinical Investigative Site 3112

    Burlington, Vermont

  • Clinical Investigative Site 3111

    Richmond, Virginia

  • Clinical Investigative Site 3102

    Kirkland, Washington

  • Clinical Investigative Site # 1001

    Fitzroy, Australia

  • Clinical Investigative Site 1000

    Westmead, Australia

  • Clinical Investigative Site 1102

    Amstetten, Austria

  • Clinical Investigative Site 1100

    Sankt Pölten, Austria

  • Clinical Investigative Site 1101

    Vienna, Austria

  • Clinical Investigative Site 1201

    La Louvière, Belgium

  • Clinical Investigative Site # 1205

    Liège, Belgium

  • Clinical Investigative Site 1204

    Ottignies, Belgium

  • Clinical Investigative Site 1203

    Sijsele-Damme, Belgium

  • Clinical Investigative Site 1302

    Sofia, Bulgaria

  • Clinical Investigative Site 1301

    Sofia, Bulgaria

  • Clinical Investigative Site 1303

    Varna, Bulgaria

  • Clinical Investigative Site 1304

    Varna, Bulgaria

  • Clinical Investigative Site # 1401

    Burnaby, Canada

  • Clinical Investigative Site 1400

    Ottawa, Canada

Showing 40 of 115 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.